A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation

Jan 27, 2025   |   Dharam J. Kumbhani, MD, SM, FACC

The goal of AZALEA-TIMI 71, a phase 2 trial, was to compare the safety and efficacy of 2 doses of abelacimab compared with rivaroxaban among patients with atrial fibrillation (AF) and a moderate–high risk of stroke.

Randomized Trial to Prevent Vascular Events in HIV

Dec 19, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the REPRIEVE trial was to evaluate pitavastatin compared with placebo among individuals with human immunodeficiency virus (HIV) infection and low-to-moderate risk of cardiovascular disease.

Myocardial Ischemia and Transfusion

Nov 12, 2024   |   Amit Saha, MD

The goal of the MINT trial was to compare the effect of a liberal vs. restrictive blood transfusion strategy on acute myocardial infarction (MI) in patients with concomitant anemia.

ExtraCorporeal Life Support for acute myocardial infarction complicated by cardiogenic shock

Sep 13, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the ECLS-SHOCK trial was to evaluate extracorporeal life support (ECLS) compared with control among patients with acute myocardial infarction (MI) and cardiogenic shock.

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Sep 12, 2024   |   Amit Saha, MD

The goal of the SELECT trial was to determine the association of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with cardiovascular (CV) events in a secondary prevention cohort of patients with overweight or...

Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation

Sep 11, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the ARTESIA trial was to evaluate apixaban compared with aspirin among patients with subclinical atrial fibrillation (AF).

Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events

Aug 09, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the ESPRIT trial was to evaluate intensive blood pressure (BP) control (systolic BP [SBP] <120 mm Hg) compared with standard BP control (SBP <140 mm Hg) among patients with hypertension.

ORBITA-2: Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

Jun 06, 2024   |   Katherine A Lang, MD; Hooman Bakhshi, MD, FACC

The ORBITA-2 (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial data demonstrate that, in patients with stable angina and ischemia producing coronary stenoses...

Thromboembolic Prevention in Atrial High-Rate Episodes: Is There Benefit? (NOAH-AFNET 6 Study)

Apr 30, 2024   |   Fengwei Zou; Luigi Di Biase, MD, PhD, FACC

Prolonged atrial arrhythmias expose patients to increased risks of thromboembolism. The results of a meta-analyses revealed a fourfold increased risk of stroke and systemic embolism in patients with atrial high-rate episodes (AHRE) lasting ≥30 sec.

Who to Select For Treatment With Semaglutide: A Look at the SELECT Trial

Apr 03, 2024   |   Dr. Melody Hermel, MD; Anthony C. Pearson, MD, FACC; Sheila Jeschke, FNP-BC

At the American Heart Association's (AHA) Scientific Sessions 2023, the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial was presented demonstrating that 2.4mg once weekly subcutaneous semaglutide...

Transfusion Threshold in Myocardial Infarction: MINT Trial

Mar 04, 2024   |   Omar Khdeir, MD; Faisal Latif, MBBS, FACC

Hemoglobin (Hb) threshold for red cell transfusion in myocardial infarction (MI) with anemia has been a matter of debate. Previous randomized trials have not consistently shown a benefit of liberal transfusion strategy.

A Randomized, Double-Blind, Dose-Ranging Study of Zilebesiran in Patients With Mild-to-Moderate Hypertension

Feb 27, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the KARDIA-1 trial was to evaluate zilebesiran compared with placebo among patients with hypertension. Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT) synthesis by RNA interference.

AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF

Feb 20, 2024   |   Alison Bailey, MD, FACC; Thomas F. Deering, MD, FACC; Jeff S. Healey, MD

In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation.

ACCEL Lite: AHA Late-Breaker: SELECT – Semaglutide and CV Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes

Jan 23, 2024   |   Alison Bailey, MD, FACC; Abraham Michael Lincoff, MD, FACC; Glenn A. Hirsch, MD, MHS, FACC

The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM.

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Jan 22, 2024   |   Dharam J. Kumbhani, MD, SM, FACC

The goal of the ATTRibute-CM trial was to compare the safety and efficacy of acoramidis compared with placebo among patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

Dec 21, 2023   |   Dharam J. Kumbhani, MD, SM, FACC

The goal of the ORBITA-2 trial was to assess the efficacy of percutaneous coronary intervention (PCI) compared with a sham placebo procedure for angina relief among patients with stable angina who were not on background antianginal medication.

AHA 2023 Scientific Sessions: Sports Cardiology Session Summary

Dec 11, 2023   |   Theodore Millette, MD; Sean P Meagher, MD; Jeffrey J Hsu, MD, PhD, FACC

This year's American Heart Association Scientific Sessions (AHA 2023) in Philadelphia featured several sessions dedicated to exercise and sports cardiology, including an expert-led session on sudden cardiac arrest (SCA) on the athletic field and...

ACCEL Lite: AHA Late-Breaker ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial

Nov 30, 2023   |   Alison Bailey, MD, FACC; William E. Boden, MD, FACC; Rasha Al-Lamee, MD; Christopher Rajkumar

In this interview, Christopher Rajkumar, MD, Rasha Al-Lamee, MD, and William E. Boden MD, FACC, discuss AHA Late-Breaker: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial.

ACCEL Lite: AHA Late-Breaker SPEC-AI: Screening for Peripartum Cardiomyopathies Using an AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

Nov 21, 2023   |   Alison Bailey, MD, FACC; Demilade Adedinsewo, MD, FACC; Steven E. Nissen, MD, MACC

In this interview, Demilade A. Adedinsewo MD, FACC, and Steven E. Nissen MD, MACC, discuss the AHA Late-Breaker: Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial.

ACCEL Lite: AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients with Acute Myocardial Infarction Without Diabetes

Nov 17, 2023   |   Alison Bailey, MD, FACC; Stefan K James, MD, PhD; Laxmi S. Mehta, MD, FACC

Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes.

Video: Day 3 — ACCess Points Daily Wrap Up | AHA 2023

Nov 13, 2023   |   ; Kim A. Eagle, MD, MACC; Ajay J. Kirtane, MD, FACC; Payal Kohli, MD, FACC; Dharam J. Kumbhani, MD, SM, FACC

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from day 3, Monday, November 13 at the American Heart Association Scientific Sessions 2023 including ESPRIT (0:34), MINT (3:54), ORFAN (8:25),...

Eagle’s Eye View: Day 3 — ACCess Points Daily Wrap Up | AHA 2023

Nov 13, 2023   |   ; Kim A. Eagle, MD, MACC; Ajay J. Kirtane, MD, FACC; Payal Kohli, MD, FACC; Dharam J. Kumbhani, MD, SM, FACC

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from day 3, Monday, November 13 at the American Heart Association Scientific Sessions 2023 including ESPRIT (0:34), MINT (3:54), ORFAN (8:25),...

ACC Cardiology Hour | AHA 2023

Nov 13, 2023   |   Valentin Fuster, MD, PhD, MACC; Joshua A. Beckman, MD, MS, FACC; Roxana Mehran, MD, FACC; Pasquale Santangeli, MD; Amanda Vest, MD, FACC

A long-standing resource for busy cardiovascular professionals, ACC Cardiology Hour offers multidisciplinary expert discussion on top clinical trials released during cardiology's biggest meetings.

New Studies Showcase Potential For AI at the Bedside

Nov 13, 2023

Artificial intelligence (AI) uses at the bedside were the focus of a late-breaking science session at AHA 2023. Studies addressed topics ranging from AI-guided screening during and after pregnancy to novel speech analysis technology that may be...

Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction With Electrocardiogram

Nov 13, 2023   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the ARISE trial was to evaluate artificial intelligence (AI)-interpreted electrocardiogram (ECG) (AI-ECG) compared with usual care among patients in the emergency department who received an ECG.